Abstract: Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth. The compression resistant implant comprises a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and a freeze-dried oxysterol in an amount of about 5 wt % to about 90 wt % of the implant. Methods of making and use are further provided.
Type:
Grant
Filed:
July 1, 2020
Date of Patent:
January 11, 2022
Assignee:
Warsaw Orthopedic, Inc.
Inventors:
Benjamin T. Reves, David S. Scher, Roger E. Harrington, Jerbrena C. Jacobs
Abstract: An implantable device comprising a substrate capable of capturing an intraocular target molecule and to methods of use thereof. The substrate may be capable of capturing a target molecule present in the eye and/or from fluid of the eye (e.g., an intraocular target molecule). In some embodiments, the substrate has a relatively high affinity for a target molecule.
Type:
Grant
Filed:
November 9, 2018
Date of Patent:
January 11, 2022
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.
Type:
Grant
Filed:
August 20, 2021
Date of Patent:
January 11, 2022
Assignee:
King Abdulaziz University
Inventors:
Imran Kazmi, Syed Sarim Imam, Muhammad Afzal, Muhammad Shahid Nadeem, Fahad A. Al-Abbasi, Firoz Anwar
Abstract: A composition that can solvate biofilms and disrupt bacterial cell walls acts to both kill the bacteria by cell lysis and remove the biofilm. This solvent-containing composition is effective against a broad spectrum of microbes and can be used on a variety of surfaces, both living and inanimate. The polarity of the solvent component of the composition is lower than that of pure water so that the composition exhibits increased efficacy in solvating the macromolecular matrix of a biofilm and in penetrating bacterial cell walls.
Abstract: The invention relates to bismuth-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods for treating a topical wound, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a bismuth-thiol compound, wherein the composition is applied to the infection. Methods for treating microbial infections such as diabetic foot infections are also provided.
Abstract: The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.
Type:
Grant
Filed:
December 21, 2020
Date of Patent:
December 21, 2021
Assignee:
Sun Pharmaceutical Industries Limited
Inventors:
Ravindra Agarwal, Tarun Singhal, Ravi Kochhar
Abstract: A composition includes a target pharmaceutical or biological agent, a solution containing the target pharmaceutical or biological agent, and substrate that is soluble in the solution. The substrate is capable of being solidified via a solidification process and the solidification process causes the substrate to become physically or chemically cross-linked, vitrified, or crystallized. As a result of the solidification process, particles are formed. The target pharmaceutical or biological agent within the solution retains proper conformation to ultimately produce a desired effect.
Type:
Grant
Filed:
July 24, 2019
Date of Patent:
December 14, 2021
Assignee:
TissueGen, Inc.
Inventors:
Jennifer Seifert, Paul R. Sood, Brent B. Crow, Kevin D. Nelson, Nickolas B. Griffin, Alpeshkumar P. Patel, Paul A. Hubbard
Abstract: An extended-release bio absorbable subcutaneous medicinal dosage delivery implant system includes an implant fabricated from a highly homogeneously mixed composition including a medicinal agent in combination with release controlling polymers which include poly (DL-lactide) and polycaprolactone. In one implementation for treating an opioid disease, the formulation composition includes naltrexone at 40 weight percent, poly (DL-lactide) in the range between 36 and 46.4 weight percent, and polycaprolactone in the range between 24 and 11.6 weight percent. In addition, in order to provide anti-biofouling quality and prevent foreign body adsorption/interaction with the material of the implant, polyethylene glycol is added in a preferred content of 2.0%. The manufacturing process includes hot melt extrusion and a mini jet based implant formation stage with the optimized process space were the temperature of the process ranges from 170° C.-180° C.
Type:
Grant
Filed:
April 9, 2021
Date of Patent:
December 14, 2021
Assignee:
Drug Delivery Company, LLC
Inventors:
Jeffrey D. Benner, Steven M. Cohen, Naresh Kumar Reddy Vutukuru, Pushkar Shrinivas Kulkarni, Srinivasan Shanmugam
Abstract: Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
Type:
Grant
Filed:
June 29, 2020
Date of Patent:
December 7, 2021
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Zelton Dave Sharp, Randy Strong, Paul Hasty, Carolina Livi, Arlan Richardson
Abstract: A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and a semifluorinated alkane, as a liquid vehicle. The topical ophthalmological composition treats an ocular disease.
Abstract: Embodiments described herein are related to pellets that are placed within an extraction site that is in need of bone augmentation and preservation. The pellets are typically cylindrical in shape and comprise a material and a polymer coating. The goal of the pellets are to encourage sufficient new bone growth that jaw bone deterioration is prevented. The pellets create, arrange, and assemble an ideal growth environment for new bone growth to rapidly grow and preserve the original contours of an individual's jaw bone.
Abstract: The present invention provides combination therapies for treating a metabolic disorder, such as type 2 diabetes, obesity, and related comorbidities (e.g., NASH or NAFLD)) in an individual undergoing treatment with a gastrointestinal implant. The combination therapies described herein include methods for treating an individual with a gastrointestinal implant with a metabolic agent, a bariatric procedure, and/or a microbiota modulator.
Abstract: A “nanolipogel” is a delivery vehicle including one or more lipid layer surrounding a hydrogel core, which may include an absorbent such as a cyclodextrin or ion-exchange resin. Nanolipogels can be constructed so as to incorporate a variety of different chemical entities that can subsequently be released in a controlled fashion. These different incorporated chemical entities can differ dramatically with respect to size and composition. Nanolipogels have been constructed to contain co-encapsulated proteins as well as small hydrophobic drugs within the interior of the lipid bilayer. Agents incorporated within nanolipogels can be released into the milieu in a controlled fashion, for example, nanolipogels provide a means of achieving simultaneous sustained release of agents that differ widely in chemical composition and molecular weight. Additionally, nanolipogels can favorably modulate biodistribution.
Type:
Grant
Filed:
December 12, 2019
Date of Patent:
November 16, 2021
Assignee:
Yale University
Inventors:
Tarek M. Fahmy, Eric Stern, Richard A. Flavell, Jason Park, Alyssa Siefert, Stephen H. Wrzesinski
Abstract: Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.
Type:
Grant
Filed:
May 31, 2017
Date of Patent:
November 16, 2021
Assignee:
Infectious Disease Research Institute
Inventors:
Neal Van Hoeven, Traci Mikasa, Christopher B. Fox, Anwar Ahniyaz, Mark T. Orr, Amit Khandhar
Abstract: The present disclosure provides an implantable device comprising a substrate capable of capturing an intraocular target molecule and to methods of use thereof.
Type:
Grant
Filed:
December 6, 2019
Date of Patent:
November 2, 2021
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Abstract: The present disclosure provides a microparticulate comprising one or more cannabinoids and a pH dependent release polymer. In embodiments, the one or more cannabinoids are present in an amount ranging from 10% w/w to about 50% w/w. In embodiments, the pH dependent release polymer is present in an amount ranging from ranging from about 5% w/w to about 85% w/w.
Abstract: Implantable materials visible under ultrasound may be delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.
Abstract: Implantable materials visible under ultrasound may be delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.
Abstract: One embodiment of the present invention is directed to compositions and methods for enhancing attachment of soft tissues to a metal prosthetic device. In one embodiment a construct is provided comprising a metal implant having a porous metal region, wherein said porous region exhibits a nano-textured surface.
Abstract: In various embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Type:
Grant
Filed:
November 30, 2020
Date of Patent:
October 12, 2021
Assignee:
Amarin Pharmaceuticals Ireland Limited
Inventors:
Mehar Manku, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski